BillionToOne Cancer Monitoring Assay Shows On-Par to Superior Results vs. Tumor-Informed Assay in Study
A new peer-reviewed study comparing BillionToOne's Tissue-Free Northstar Response® assay to tumor-informed ctDNA testing found 94% concordance. In discordant cases, the clinical ground-truth supported Northstar Response®.